Forma Therapeutics Holdings, Inc. – NASDAQ:FMTX

Add to watchlist

$20.01

+20.01

Market closed

Open in 2 days

-100.00%

month

-100.00%

quarter

-100.00%

year

Market Cap	N/A
Enterprise value	913.99M

P/E	-5.23
EV/Sales	N/A
EV/EBITDA	-4.89
Price/Sales	N/A
Price/Book	2.30
PEG ratio	0.17
EPS	-4

Revenue	N/A
EBITDA	-186.67M
Income	-190.15M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX): Profit margin
Sep 2021	0	-43.29M
Dec 2021	0	-50.12M
Mar 2022	0	-44.15M
Jun 2022	0	-52.57M

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX): Earnings per share (EPS)
2022-03-01	-0.96	-1.06
2022-05-06	-1.05	-0.93
2022-08-05	-0.99	-1.1

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX): Debt to assets
Sep 2021	602225000	59.39M	9.86%
Dec 2021	561061000	62.70M	11.18%
Mar 2022	514497000	53.30M	10.36%
Jun 2022	475169000	60.67M	12.77%

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX): Cash Flow
Sep 2021	-34.80M	71.59M	-414K
Dec 2021	-41.20M	30.99M	30K
Mar 2022	-49.29M	45.66M	662K
Jun 2022	-44.76M	45.52M	-39K

Forma Therapeutics Holdings alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Forma Therapeutics Holdings
Employees

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX): Employee count
Aug 2023	189
Sep 2023	189
Oct 2023	189
Nov 2023	189
Dec 2023	189
Jan 2024	189
Feb 2024	189
Mar 2024	189
Apr 2024	189
May 2024	189
Jun 2024	189
Jul 2024	189

Forma Therapeutics Holdings
Hedge Funds Holdings Q3 2022

83.88% -4.19%

of FMTX is owned by hedge funds

130 +25

hedge funds hold FMTX stock

39.73M -1.98M

shares is hold by hedge funds

FMTX hedge funds holdings changes

Forma Therapeutics Holdings
Insider Trading

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX): Insider trades (number of shares)
Period	Buy	Sel
Feb 2022	0	45637

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	13 Apr 2022	KELLY PATRICK F. officer: SVP, Chi..	Stock Option (Right to Buy)	15,000	$5.05	$75,750
Option	8 Apr 2022	KELLY PATRICK F. officer: SVP, Chi..	Common Stock	15,000	$5.05	$75,750
Sale	23 Feb 2022	WADLINGER MARY E. officer: Officer Title: SVP, Corporate A.. officer: Officer Title: SVP, Co..	Common Stock	4,684	$9.78	$45,800
Sale	23 Feb 2022	LESSER BRIAN ANDREW officer: SVP, Commercial officer: SVP, Commercial	Common Stock	3,837	$9.78	$37,518
Sale	23 Feb 2022	SHEGOG TODD officer: SVP, Chi..	Common Stock	5,687	$9.78	$55,607
Sale	23 Feb 2022	COOK DAVID N officer: SVP, Chief Scientific Officer officer: SVP, Chief Scientific ..	Common Stock	3,531	$9.78	$34,526
Sale	23 Feb 2022	POTTS JEANNETTE officer: Officer Title: SVP, General Couns.. officer: Officer Title: SVP, Ge..	Common Stock	4,672	$9.78	$45,683
Sale	23 Feb 2022	KELLY PATRICK F. officer: SVP, Chi..	Common Stock	5,245	$9.78	$51,286
Sale	23 Feb 2022	LEE FRANK D. director, officer..	Common Stock	17,981	$9.78	$175,818
Option	6 Jan 2021	POTTS JEANNETTE officer: See Remarks officer: See Remarks	Stock Option (Right to Buy)	3,400	$5.05	$17,170

FMTX insider trading transactions

Forma Therapeutics Holdings
Earnings Call Transcripts

Quarter	Transcript
Q2 2022 5 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 6 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 1 Mar 2022	Q4 2021 Earnings Call Transcript
Q3 2021 12 Nov 2021	Q3 2021 Earnings Call Transcript

FMTX earnings call transcripts

Forma Therapeutics Holdings
Executives

Insider	Age	Compensation
Mr. Frank D. Lee (1968) Pres, Chief Executive Officer & Director	57	$2,420,000
Mr. Todd E. Shegog (1965) Senior Vice President & Chief Financial Officer	60	$706,850
Dr. Patrick F. Kelly M.D. (1964) Senior Vice President & Chief Medical Officer	61	$655,290

Forma Therapeutics Holdings
Latest News

Friday, 14 October 2022
08:35	Novo Nordisk announces the completion of the Forma Therapeutics acquisition	globenewswire.com
Tuesday, 27 September 2022
11:42	FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX	businesswire.com
Monday, 26 September 2022
00:00	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY	prnewswire.com
Monday, 19 September 2022
01:43	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IEA, CYBE, FMTX, TRQ	prnewswire.com
Friday, 2 September 2022
22:38	Forma Therapeutics shares jump 50%; here is why	Invezz
Thursday, 1 September 2022
14:36	Why Forma Therapeutics Holdings Stock Is On Fire Today	The Motley Fool
12:14	Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout	Investors Business Daily
09:20	Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion	Pulse2
08:19	Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal	Reuters
08:18	Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion	Market Watch
Wednesday, 31 August 2022
10:32	Forma Therapeutics: Rare Disease Play	Seeking Alpha
Friday, 5 August 2022
10:21	Forma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Friday, 29 July 2022
07:05	Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022	Business Wire
Wednesday, 22 June 2022
11:35	Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?	Zacks Investment Research
Wednesday, 15 June 2022
11:34	Bears are Losing Control Over Forma Therapeutics Holdings, Inc. (FMTX), Here's Why It's a 'Buy' Now	Zacks Investment Research
Friday, 3 June 2022
07:05	Forma Therapeutics to Present at the Jefferies Healthcare Conference	Business Wire
Friday, 6 May 2022
12:30	Forma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Friday, 29 April 2022
07:05	Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022	Business Wire
Tuesday, 1 March 2022
13:09	Forma Therapeutics Holdings' (FMTX) CEO Frank Lee on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 23 February 2022
07:05	Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022	Business Wire
Tuesday, 8 February 2022
07:05	Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference	Business Wire
Friday, 7 January 2022
07:05	Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference	Business Wire
Thursday, 30 December 2021
11:29	Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 277% to Reach the Level Wall Street Analysts Expect?	Zacks Investment Research
Tuesday, 28 December 2021
06:55	Forma Therapeutics (FMTX) Sees Hammer Chart Pattern: Time to Buy?	Zacks Investment Research
Monday, 13 December 2021
12:16	Forma's (FMTX) Etavopivat Proves Safety Profile in SCD Study	Zacks Investment Research
Wednesday, 24 November 2021
08:29	Forma Therapeutics (FMTX) Sees Hammer Chart Pattern: Time to Buy?	Zacks Investment Research
Thursday, 18 November 2021
11:28	How Much Upside is Left in Forma Therapeutics Holdings, Inc. (FMTX)? Wall Street Analysts Think 185%	Zacks Investment Research
Friday, 12 November 2021
13:09	Forma Therapeutics Holdings, Inc. (FMTX) CEO Frank Lee on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Friday, 5 November 2021
07:05	Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021	Business Wire
Thursday, 7 October 2021
07:05	Forma Therapeutics' FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer	Business Wire

Ideas & Opinions

Seeking Alpha 31 Aug 2022

Forma Therapeutics: Rare Disease Play
Seeking Alpha 2 Jun 2021

ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas

Frequently Asked Questions (FAQ)

What's the price of Forma Therapeutics Holdings stock today?

One share of Forma Therapeutics Holdings stock can currently be purchased for approximately $20.01.
When is Forma Therapeutics Holdings's next earnings date?

Unfortunately, Forma Therapeutics Holdings's (FMTX) next earnings date is currently unknown.
Does Forma Therapeutics Holdings pay dividends?

No, Forma Therapeutics Holdings does not pay dividends.
What is Forma Therapeutics Holdings's stock symbol?

Forma Therapeutics Holdings, Inc. is traded on the NASDAQ under the ticker symbol "FMTX".
What is Forma Therapeutics Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Forma Therapeutics Holdings?

Shares of Forma Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Forma Therapeutics Holdings's key executives?
Forma Therapeutics Holdings's management team includes the following people:
- Mr. Frank D. Lee Pres, Chief Executive Officer & Director(age: 57, pay: $2,420,000)
- Mr. Todd E. Shegog Senior Vice President & Chief Financial Officer(age: 60, pay: $706,850)
- Dr. Patrick F. Kelly M.D. Senior Vice President & Chief Medical Officer(age: 61, pay: $655,290)
How many employees does Forma Therapeutics Holdings have?

As Jul 2024, Forma Therapeutics Holdings employs 189 workers.
When Forma Therapeutics Holdings went public?

Forma Therapeutics Holdings, Inc. is publicly traded company for more then 5 years since IPO on 19 Jun 2020.
What is Forma Therapeutics Holdings's official website?

The official website for Forma Therapeutics Holdings is formatherapeutics.com.
Where are Forma Therapeutics Holdings's headquarters?

Forma Therapeutics Holdings is headquartered at 500 Arsenal Street, Watertown, MA.
How can i contact Forma Therapeutics Holdings?

Forma Therapeutics Holdings's mailing address is 500 Arsenal Street, Watertown, MA and company can be reached via phone at +61 76791970.

Forma Therapeutics Holdings, Inc.

formatherapeutics.com

Exchange:

NASDAQ

Full time employees:

189

Industry:

Biotechnology

Sector:

Healthcare

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.

+61 76791970

500 Arsenal Street
Watertown, MA 02472

CIK: 0001538927
ISIN: US34633R1041
CUSIP: 34633R104